{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-087631","form_type":"8-K","ticker":"FENC","cik":"0001211583","company_name":"FENNEC PHARMACEUTICALS INC.","filed_at":"2023-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.342028+00:00","generated_at":"2026-06-12T05:41:43.459488+00:00","sec_items":["5.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Fennec Q2 revenue $3.3M (up 98% QoQ); appoints Adrian Haigh as COO","bullets":["Net product sales of $3.3M for Q2 2023, up 98% from Q1 2023; gross profit $3.2M.","Net loss of $5.4M ($0.21 diluted EPS) vs $5.1M loss ($0.19) in Q2 2022.","Cash and equivalents $15.0M; sufficient to fund operations for at least 12 months.","Adrian Haigh appointed COO, stepping down from board; base salary €400K/yr plus bonus and 200K options.","Management to present at 2023 Wedbush PacGrow Healthcare Conference on August 8-9."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-087631","json":"https://secwatch.observer/filing/0001104659-23-087631.json","markdown":"https://secwatch.observer/filing/0001104659-23-087631.md","text":"https://secwatch.observer/filing/0001104659-23-087631.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1211583/000110465923087631/0001104659-23-087631-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1211583/000110465923087631/tm2322902d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T05:41:43.459488+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cb3b650e8f","claim":"Adrian Haigh was appointed as Chief Commercial Officer at FENNEC PHARMACEUTICALS INC..","evidence_excerpt":"In the same press release it was announced that Mr. Haigh had accepted the appointment as Chief Commercial Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1211583/000110465923087631/0001104659-23-087631-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Commercial Officer"}],"fact_type":"executive_change"},{"claim_id":"d6bea02a01","claim":"Adrian Haigh departed as Director at FENNEC PHARMACEUTICALS INC..","evidence_excerpt":"Adrian Haigh had stepped down from the the position of Director of Fennec Pharmaceuticals Inc.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1211583/000110465923087631/0001104659-23-087631-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"stepped down"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}